Hello Steve – I’m fairly certain Onlyfacts has it right.
GSK have been working on a replacement for several years and took up a partnering arrangement with NanoBio back around July 2010.
Next advance in the treatment of cold sores
Strengthens a key OTC franchise
NanoBio Corporation and GlaxoSmithKline plc (GSK) today announced an exclusive licensing agreement in the United States and Canada for the over-the-counter (OTC) use of NB-001, a novel, patented compound representing the next advance in the treatment of cold sores. Developed by NanoBio, NB-001 provides significant antimicrobial activity against the virus that causes cold sores, herpes labialis.
Cold sores are a prevalent condition affecting approximately 20% of the adult population in the US.
GSK has established Abreva® as the leading cold sore treatment with a greater than 50% share, gaining two share points in the prior 12 months. Abreva is the only OTC medicine approved by the US Food & Drug Administration that is proven to shorten cold sore healing time.
NanoBio has completed two Phase 2 clinical trials of NB-001, demonstrating clear efficacy and a good safety profile in patients and plans to enter Phase 3 testing soon.
Under the terms of the agreement, NanoBio will receive an upfront payment of $14.5 million, and is eligible to receive additional milestone payments of up to $40 million plus single digit royalties on future sales.
Two large Phase 3 clinical studies were initiated in the spring of 2011 with results expected in 2012 I have not followed up on it lately.
Which ever way I look at it Abreva has served us well, right up to the last.
I'm pretty sure it just stops with no payment. The end of royalties occurs with expiration of the patent. GSK will take a pricing hit as a result but it seems they are trying to pump up the brand and will try to hang on to it.